The Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM) was founded on a $285 million public-private partnership between HHS and collaborating academic, commercial and State of Texas stakeholders. It is one of three national centers for innovation supported by the U.S. Department of Health and Human Services.
The 12.5-acre site encompasses the Pandemic Influenza Vaccine Facility (PIF) and the Live Virus Vaccine Facility (LVVF), as well as future building areas, parking and vehicular circulation, service areas and landscape/pedestrian hardscape areas.
Pandemic Influenza Vaccine Facility
This state-of-the-art, influenza vaccine manufacturing facility supports the nation’s preparedness and response to public health threats and is capable of producing up to 50 million influenza vaccine doses within four months of receipt of a virus strain.The facility features manufacturing support areas, quality control laboratories and administrative spaces.
Live Virus Vaccine Facility
This facility comprises BioSafety Level 1 and three manufacturing areas, seed development labs, warehouse/office areas and building support spaces.
